AIGH Capital Management LLC Buys 551,725 Shares of Coya Therapeutics, Inc. (NASDAQ:COYA)

AIGH Capital Management LLC lifted its holdings in shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) by 85.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,201,152 shares of the company's stock after purchasing an additional 551,725 shares during the period. Coya Therapeutics comprises approximately 2.2% of AIGH Capital Management LLC's investment portfolio, making the stock its 17th largest holding. AIGH Capital Management LLC owned 7.19% of Coya Therapeutics worth $6,883,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in COYA. Newbridge Financial Services Group Inc. bought a new stake in Coya Therapeutics in the fourth quarter worth about $401,000. CM Management LLC raised its holdings in shares of Coya Therapeutics by 11.1% in the 4th quarter. CM Management LLC now owns 160,000 shares of the company's stock worth $917,000 after purchasing an additional 15,941 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Coya Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company's stock valued at $918,000 after purchasing an additional 4,485 shares during the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on COYA shares. Chardan Capital reissued a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Thursday, March 20th. D. Boral Capital reissued a "buy" rating and issued a $18.00 price objective on shares of Coya Therapeutics in a report on Thursday, March 27th.

Coya Therapeutics Stock Performance

Coya Therapeutics stock traded down $0.24 during mid-day trading on Thursday, reaching $6.30. The company's stock had a trading volume of 30,677 shares, compared to its average volume of 70,195. The company has a market capitalization of $105.37 million, a P/E ratio of -9.69 and a beta of 0.31. The firm's fifty day moving average price is $6.48 and its two-hundred day moving average price is $6.52. Coya Therapeutics, Inc. has a 12-month low of $4.75 and a 12-month high of $10.24.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.14. The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.10 million. On average, research analysts predict that Coya Therapeutics, Inc. will post -1.15 EPS for the current fiscal year.

Coya Therapeutics Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.